No Data
No Data
Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low
Why These Top ASX 200 Growth Shares Could Rise 35%+ in 2025
3 Fantastic ASX 200 Growth Shares to Buy in 2025
Neuren Pharmaceuticals Says Partner Acadia Completes Sale of Rare Pediatric Disease Priority Review Voucher
Neuren Pharmaceuticals Limited's (ASX:NEU) Intrinsic Value Is Potentially 60% Above Its Share Price
My 2 Best ASX Growth Shares to Buy in November